Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis.
A patient with low-grade non-Hodgkin's lymphoma (NHL) who relapsed shortly after an allogeneic bone marrow transplant (BMT) is reported. The patient was treated with interleukin 2 (IL-2), which resulted in a flare-up of graft-versus-host disease followed by disease control, with disappearance of peripheral lymphadenopathy. Sequential bone marrow testing showed the disappearance of bone marrow involvement with disease but occurrence of T-cell aggregates post IL-2 that were identified as polyclonal by molecular methods. The patient remains in complete remission 37 months following allogeneic BMT.
Kiss
Thomas L
TL
Bone Marrow Transplant Service, Department of Medical Oncology and Haematology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Canada.
Spaner
David
D
Daly
Andrew S
AS
Hasegawa
Wanda S
WS
Lipton
Jeffrey H
JH
Messner
Hans A
HA
Chang
Hong
H
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D005500:Follow-Up Studies; D006087:Graft vs Host Reaction; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy*; D008218:Lymphocytosis / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D012008:Recurrence
D000970:Antineoplastic Agents; D007376:Interleukin-2